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Abstract 
As large animal models continue to play an important role in translating lung-directed therapeutic strategies from 
laboratory animals to man, there is an increasing interest in the analysis of endogenous regulators of inflammation at 
both a genomic and a therapeutic level. To this end we have sought to characterise the ovine ortholog of elafin, an 
important regulator of inflammation in man. We have isolated both the elafin cDNA and gene which have a similar 
structure to other species orthologs. Interestingly, we have isolated two alleles for ovine elafin, which contain a very 
high number of transglutamination repeats, thought to be important in binding elafin to the interstitium. The mainly 
mucosal mRNA distribution for ovine elafin suggests that ovine elafin may, like its human ortholog, have functions 
in innate immunity. This is supported by analysis of elafin and the related protein SLPI in ovine bronchoalveolar 
fluid in response to locally administered lipopolysaccharide and confirmation of them acting as ‘alarm’ 
antiproteases. We have also cloned the ovine elafin cDNA into an adenoviral vector and have demonstrated correct 
processing of the secreted protein as well as biological activity. Over-expression of ovine elafin in a lung-derived 
epithelial cell line has a protective effect against the enzymes human neutrophil and porcine pancreatic elastase. The 
identification of the ovine elafin gene and its translated protein are important in developing practical strategies 
aimed at regulating inflammation in the large mammalian lung. 
 
 
 
 
 
Keywords : anti-protease, elastase, sheep, trappin. 
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Abbreviations 
SLPI : secretory leukoprotease inhibitor; BAC : bacterial artificial chromosome; RACE : rapid amplification of 
cDNA ends; WAP : whey acidic protein; REST : rapidly evolving seminal vesicle transcribed; TOM : trappin ovine 
molecule; HNE : human neutrophil elastase; PPE : porcine pancreatic elastase; EIC : elastase inhibitory capacity; 
PAGE : polyacrylamide gel electrophoresis; UTR : untranslated region; LPS : lipopolysaccharide. 
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Introduction  
 
The trappins (acronym for TRansglutaminase substrate and WAP (whey acidic protein) domain containing ProteIN, 
(27)) are a group of proteins characterized by the presence of a N-terminal transglutaminase substrate (“cementoin”) 
domain and a C-disulphide core domain, also called WAP domain, which contains, in some members, an 
antiproteinase active site. Current knowledge suggests that the two domains may have evolved from exon shuffling 
and gene duplication between rapidly evolving seminal vesicle transcribed (REST) genes and the WAP domains of 
ancestral genes (3). Indeed, in humans, co-localisation of the human trappin-2 gene (also known as elafin/elastase-
specific-inhibitor/SKALP) and the secretory leukocyte protease inhibitor (SLPI) gene (which contains two WAP 
domains) in the same region of chromosome 20 is in agreement with this hypothesis (8, 12). Our group is 
particularly interested in the study of elafin which was identified as an anti-elastase inhibitor in the early 90s (19, 21, 
26, 35). The closely related protein SLPI also has important functions as an inhibitor of neutrophil elastase (20 and 
references therein) and both molecules have been found to be present in man at mucosal sites and also have been 
shown to be synthesized by epithelial cells and alveolar macrophages. In addition, it has recently been demonstrated 
that both elafin and SLPI have antimicrobial functions and may be able to prime the innate immune system (20). 
More than fifteen trappins and many more WAP-containing proteins have been identified to date, throughout the 
animal kingdom. Although the sequence in the WAP domain predicts that a number of trappin species orthologs are 
anti-elastase molecules, this has only formally been demonstrated for human and porcine elafin, (19, 21, 26, 32, 35). 
Because of our interest in the modulation of lung inflammation in ovine models (2), and the known modulatory 
activity of antiproteases (20) we set out to isolate the ovine elafin cDNA and gene ortholog and to study its 
properties. 
 
We identified in this study two allelic forms of the ovine elafin gene (named TOM-1 and TOM-2 for “Trappin-
Ovine Molecule” 1 & 2) and analysed their mRNA distribution in a variety of tissues. Furthermore, we have 
demonstrated that secreted ovine elafin can protect a lung derived epithelial cell line from proteolytic damage due to 
both human neutrophil elastase and porcine pancreatic elastase. The distribution, anti-elastase activities and kinetics 
of expression in-vivo of ovine elafin predict that it may also have mucosal protective functions in inflammation. This 
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should prove a valuable tool in developing therapeutic strategies in a large animal model of lung inflammation, 
currently being developed in our laboratories. 
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Experimental Procedures 
 
 
Molecular biology reagents 
Primers were synthesised and supplied by MWG-Biotech AG (Milton Keynes, UK). Primer design for 5’RACE 
(GSP1) was based on preliminary ovine elafin sequence (R. Mistry, unpublished data). Subsequent primers were 
based on the newly determined ovine elafin sequence. Elafin gene-specific reverse primer (GSP1) 5’- CAT GGC 
GCA CCG GAT CA - 3’ ; Elafin gene-specific forward primer (GSP2) 5’- ATG AAG ACC AGA AGC TTC TTG 
GTC C - 3’; Full length reverse primer (r-el) 5’- CTG GGG ATC CAT ACA GGT CTT – 3’; Bgl II forward elafin 
primer (Bgl-f-el) 5’- GCC GGA GAT CTG ACA ACA TGA AGA CCA GAA GCT TCT TGG TC – 3’ (Bgl II site 
underlined; Kozak sequence in bold); Sac I elafin reverse primer (Sac-r-el) 5’- TAC GTG AGC TCT CAT CAC 
TGG GGA TCC ATA CAG GTC TT – 3’ (Sac I site underlined); Forward BAC primer (fBAC) 5’- TGA AAA 
GGG TCC AAT CAA CG – 3’; Reverse BAC primer (rBAC) 5’- GAG CCA CGC TTA GTG AGG AG – 3’. 
Taq DNA polymerase, magnesium chloride 25mM, DNA polymerase buffer, dNTPs, oligo (dT) primer, EcoR1, 
Buffer H for EcoR1, BglII, Buffer D for BglII, Sac I, Buffer J for SacI, M-MLV reverse transcriptase, 5x M-MLV 
RT buffer were supplied by Promega UK (Southampton, UK).  
Shuttle vector pDC516 was obtained from Microbix Biosystems Inc. (Toronto, Canada). Shuttle vector pIRES-
GFP#3 was kindly donated by Dr. Mary Hitt (Dept. of Pathology and Molecular Medicine, McMaster University, 
Hamilton, Ontario, Canada). 
 
RNA preparation and Rapid amplification of cDNA ends (RACE) 
Ovine tissues were obtained locally from a selection of 5 month old crossbred lambs (Moredun Institute, Edinburgh, 
UK). The tissue samples obtained from sheep organs were treated as follows. Samples of each tissue were removed 
at autopsy and frozen at –80oC. Approximately one gram of each of these was then homogenised and the RNA 
extracted using Trizol (Invitrogen, Paisley, UK). RNA quality was assessed by running 10µl on a 1% agarose gel. 
Quantification of RNA in samples was by dual wavelength spectrophotometry. 
 
RACE-PCR for ovine elafin was performed using ovine tracheal mucosal RNA. Firstly in order to obtain 5’ 
information, we used a primer specific for ovine elafin, GSP1 (derived from partial sequence already obtained from 
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preliminary experiments, not shown), and the 5’ forward Generace Primer. This was followed by a nested PCR 
using GSP1 and nested 5’ forward Generace Primer. Cycling parameters were as follows: initial incubation of 92oC 
for 5 minutes, followed by 92oC 1 minute, 55oC 1 minute, and 72oC for 1 minute (30 cycles followed by a final 
amplification step of 72oC for 5 minutes). Products were run out on a 1% agarose gel. These conditions were used 
for both the original and nested PCRs.  
To perform the 3’RACE a slightly different strategy was used. Reverse transcription of the original RNA sample 
was performed using the Generace oligo-dT supplied in the GeneracerTM kit and M-MLV RT (Promega). PCR was 
then performed using the forward primer GSP2 and the reverse Generace primer in order to obtain the full-length 
cDNA sequence. GSP2 was designed from the sequence derived from the 5’RACE procedure. PCR conditions were 
similar to those above except for a magnesium chloride concentration of 2.2mM. This was followed by a nested 
PCR using GSP2 and nested reverse Generace primer. 
 
DNA Preparation and Sequence Analysis 
Genomic DNA was extracted from lung and liver samples of the above animals by proteinase K digestion in NTES 
(50mM Tris, 50mM EDTA, 100mM NaCl, 1% SDS, pH 8), followed by phenol/chloroform extraction and washing 
with 100% isopropanol followed by 70% ethanol. The DNA was re-suspended in water and kept at -20 oC. 
DNA Sequence analysis was done both in house and by MWG-Biotech AG, and the sequence data analysed with the 
on-line computer software packages NCBI Open Reading frame finder (NCBI), NCBI Blast (NCBI) and BCM 
Multiple Sequence Alignment tools (BCM).  
 
Extraction of PCR products and cloning reactions 
All PCR products were run on 1% agarose gels and bands of interest were cut out and purified using the QIAQuick 
Gel Extraction Kit (Qiagen, Crawley, W. Sussex).  
Cloning of the extracted RACE cDNA fragments was achieved by using the TOPO TA CloningR Kit for Sequencing 
included with the GeneRacerTM kit. The cDNAs were ligated into pCRR4-TOPOR plasmid followed by 
transformation into TOP10 E.coli cells (Invitrogen). Plasmid DNA was purified with the Promega SV Miniprep 
system.  
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Bacterial Artificial Chromosome (BAC) library screening and subcloning 
An ovine BAC library was screened using primers specific for elafin by Dr. F. Piumi at Institut National de la 
Recherche Agronomique (INRA), Laboratoire mixte INRA-CEA de Radiobiologie et d'Etude du Genome (LREG), 
Jouy-en-Josas, France. One positive clone was isolated and DNA prepared with Qiagen Plasmid Maxi Kit (Qiagen, 
Crawley, UK). 1µg of the BAC positive clone was digested with EcoR1, run out on a 1% agarose gel, and blotted 
onto GeneScreenTM membranes (PerkinElmer Life Sciences (UK) Ltd, Cambridge, UK). This was probed for one 
hour with [α-32P]dCTP labelled full length cDNA coding for ovine elafin, using Express-HybTM (Clontech, Palo 
Alto, USA) following the manufacturers protocol. Positive bands were identified with a Storm Phosphoimager 
system (Amersham Biosciences UK Ltd., Little Chalfont, UK) and further subcloned into plasmid PDC516 for 
sequencing using various internal primers. 
 
Tissue screening of ovine elafin by Northern Blot and RT-PCR analysis 
Twenty µg of each tissue RNA sample were denatured in 50% formamide, 16% formaldehyde, 20mM MOPS, pH 
7.0, 5mM sodium acetate, and 1mM EDTA, for 15 minutes at 65°C, electrophoresed in a 1% agarose gel containing 
2.2M formaldehyde and transferred to GeneScreenTM membrane. The membrane was hybridised with [α-32P]dCTP 
labelled full length cDNA coding for ovine elafin in ExpressHybTM following the manufacturer’s recommendations. 
The membrane was then visualised on a StormTM Phosphoimager system. 
One µg of each tissue RNA sample was used in a reverse transcriptase reaction using M-MLV RT (Promega). 
Product from this reaction was split into two PCRs, using either forward and reverse ß-actin primers or the full 
length elafin primers GSP-2 and r-el. Conditions were as for the RACE elafin PCR except for there being 35 cycles 
for elafin and 28 cycles for the ß-actin. 
 
Comparison of ovine elafin products synthesised by PCR from positive BAC clone, genomic DNA and RT-
PCR synthesised cDNA 
In order to compare the elafin cDNA, identified by the RACE procedure, with the gene sequences, PCR was 
performed using as template purified elafin BAC DNA and ovine liver DNA alongside cDNA synthesised from 
ovine skin and pIRES-GFP-ovine elafin, using the non intron-spanning primers fBAC and rBAC. PCR parameters 
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were as for the RACE elafin PCR. Products from the genomic DNA PCR were ligated into pCRR4-TOPOR plasmid 
which was transformed into TOP10 E.coli cells. Plasmid was extracted with Promega SV Miniprep system and 
elafin sequences were sequenced. 
An additional PCR was performed on ovine genomic DNA using the primers GSP2 and r-el. Products from this 
PCR were also cloned into pCRR4-TOPOR as above and sequenced.  
 
Phylogenetic Tree Analysis of WAP domains of the elafin and SLPI family members 
 
To investigate the phylogenetic relationships of the ovine forms of elafin we constructed a phylogenetic tree by the 
neighbour-joining method (18) using data from multiple alignment of the amino acid sequences of the whey acidic 
protein (WAP) domains of members of the trappin family, the known SLPI sequences (human, mouse, rat, pig and 
sheep), the murine elafin-like proteins 1 and 2 (5), and the human vasopressin molecule which contains a 
rudimentary WAP motif and can be assumed to be evolutionarily related to the elafin and SLPI families of proteins.  
 
LPS-induced up-regulation of ovine elafin and SLPI in bronchoalveolar lavage fluid 
Bronchoalveolar lavage fluid was collected to assess the regulation of ovine elafin and SLPI following local lung 
challenge with LPS. Briefly, twelve cross-bred sheep (10 female and 2 male) were anaesthetised with 20mg/kg 
intravenous thipoentone (Intraval sodium, Merial Animal Health Ltd., Harlow, Essex, UK), intubated and 
maintained on 2-3% halothane in oxygen and nitrous oxide. 1mg lipopolysaccharide (LPS) from E. coli O26:B6 
diluted in 5ml distilled water was instilled via bronchoscope into random segments. Bronchoalveolar lavages from 
these sheep were collected a week prior to the experiment and 6, 24 and 168 hours after the administration of LPS. 
The lavages were spun at 400g for 7 minutes and 200µl of the resultant supernatant was used in a dot blot onto 
GeneScreenTM membrane and blocked with 5% milk powder in TPBS. The membrane was then probed with either 
polyclonal anti-human SLPI antibody (24) or monoclonal Trab-2O anti-elafin antibody (Hycult, Nl). Resultant films 
after exposure to X-omat radiograph-quality film were scanned and densitometry measurements taken using a UVP 
white light Transilluminator (UVP, Inc. Upland, CA USA). Control membranes probed with secondary antibody 
alone showed no detectable protein (not shown). 
 
Construction of Adenoviral vector expressing ovine elafin 
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Full length ovine elafin cDNA in pCRR4-TOPOR  (see above) was used as a template for two consecutive PCRs with 
firstly Bgl-f-el and FLAG-r-el, followed by Bgl-f-el and Sac-r-FLAG-el (to yield BglII-elafin-FLAG-SacI). PCR 
conditions were as for the RACE PCR for elafin. This product was ligated into shuttle vector pDC516 (which 
contains the murine cytomegalovirus (MCMV) promoter) using standard techniques.  
This plasmid was used to create a replication-deficient adenovirus (Ad) by cotransfection of 293 cells with 
pBHGfrt(del)E1,3FLP (a kind gift from Dr. M. Hitt, McMaster University). Ad-ovine elafin was obtained through 
homologous recombination between the two plasmids using the FLP recombinase/frt mechanism (15). 
The presence of the correctly inserted ovine elafin cDNA into the viral genome was confirmed by Hind III digestion 
followed by Southern blot analysis (not shown). Infection of A549 cells with this virus confirmed correct processing 
of the ovine elafin protein (not shown). 
 
Adenovirus-mediated protection of A549 cells against proteolytic enzyme damage 
A549 cells (11) were plated out in 48 wells plates at 50,000 per well and kept in Dulbecco’s Modified Eagle’s 
Medium (DMEM) containing 10% foetal calf serum (FCS), penicillin G (final concentration 100U/ml), 
streptomycin sulphate (final concentration 100µg/ml) and L-glutamine (final concentration 2µM) overnight at 37°. 
The following day the cells were washed with fresh medium and incubated for 45 minutes with Ad-ovine elafin, Ad-
human elafin (25), Ad-murine SLPI (6), or Ad-murine Eotaxin (6) in fresh medium. The cells were then washed 
with serum free DMEM and medium replaced with DMEM containing 2% USG serum substitute (Gibco, BRL). 
After 72hrs the medium was removed, the cells washed twice with PBS and medium replaced with fresh DMEM 
with no serum or USG and containing 1µg/ml human neutrophil elastase (HNE) (Elastin Products Company, Inc., 
Missouri, USA) or porcine pancreatic elastase (PPE) (Sigma-Aldrich Co. Ltd., Dorset, UK). Plates were incubated 
overnight and photomicrographs taken.  
To quantify elastase-mediated injury, medium containing detached cells was spun at 13,000 rpm for 5 minutes. The 
cell pellet was then washed in sterile PBS twice and re-suspended in distilled water, followed by two successive 
freeze/thaw rounds. The suspension was further centrifuged (13,000rpm, 5 minutes) and the supernatant was 
assessed for protein content (indirect read-out of cell detachment) using the bicinchoninic acid method (Pierce) using 
purified albumin (Pierce) as standards. 
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Residual HNE and PPE activity in the supernatants was assayed in 96 well microtitre plates. 10µl of supernatant 
diluted with 40µl assay buffer (50mM Tris, 0.1% Triton, 0.5M NaCl, pH 8.0) was incubated at 37°C with the 
chromogenic substrates N-methoxysuccinyl-ala-ala-pro-val-p-nitroanilide (for HNE activity) or N-succinyl-ala-ala-
ala-p-nitroanilide (for PPE activity) diluted to 1µg/ml in assay buffer. Both chromogenic substrates were supplied by 
Sigma-Aldrich Co. Ltd, Dorset, UK. Enzyme activity was shown by a change in absorbance measured at 405nm 
over 90 minutes. 
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Results 
 
Isolation and sequence analysis of ovine elafin cDNA 
 
Using ovine tracheal mucosal RNA, and PCR primers annealing to a portion of the ovine elafin sequence already 
available (Mistry et al, unpublished) 5’ RACE PCR produced a product of 612bps which was cloned into pCRR4-
TOPOR plasmid for sequencing. This PCR product contained the sequence corresponding to the GeneracerR oligo 
ligated to the 5’ terminus of the mRNA followed by 18bps of 5’UTR and the ovine elafin cDNA sequence through 
to the priming site for the gene-specific primer. This information allowed 3’ RACE to proceed. This yielded a 
product of 887bps which was also cloned into pCRR4-TOPOR plasmid for sequencing and was shown to contain 
sequence 3’ of the stop codon corresponding to 3’ UTR through to the polyadenylation signal. This product 
terminated with the sequence corresponding to the GeneracerR oligo dT sequence used in the reverse transcription 
step of the RACE procedure. Altogether, the 5’ and 3’ RACE procedure allowed us to identify an open reading 
frame for a protein of 220 amino acids which showed homology with human, simian, porcine and bovine elafin (see 
fig. 1) and will be referred to as ovine elafin. The protein consists of a putative hydrophobic signal sequence of 23 
amino acids at the N terminus followed by a distinct region of hexapeptide repeats of consensus sequence PVKGQD 
which corresponds to a potential transglutaminase substrate domain (27), and a C terminal portion containing a 
presumed disulphide core region with eight cysteine residues in positions corresponding to those in the human elafin 
protein WAP domain.  
 
Sequence analysis of the ovine elafin gene 
 
Screening of an ovine BAC library was performed at the Institut National de la Recherche Agronomique (INRA) 
using probes generated by PCR (see materials and methods). This screening identified one clone for elafin. Southern 
blot analysis using 1µg of BAC clone DNA allowed identification of a positive EcoR1 band of approximately 10kb 
from the elafin clone. This band was purified and subcloned into PDC516 for sequencing with sequential internal 
primers through to the polyadenylation signal at the 3’ end and proximally through towards the promoter region. 
This approach only enabled us to obtain full 3’ sequence information (up to the polyA signal) and no 5’ information. 
Indeed, because the BAC library was generated by partial Hind III digestion, and since the elafin 5’ promoter region 
contains a Hind III site, we were unable to obtain 5’ information using this methodology and only obtained sequence 
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from this restriction site forwards. The elafin promoter region sequence was obtained by using PCR (with ovine 
genomic DNA as template obtained locally – see Materials and Methods) with a primer designed to anneal to the 5’ 
end of the human elafin promoter along with a reverse primer annealing to a portion of the first intron of the ovine 
elafin gene. This PCR product was cloned into pCRR4-TOPOR and sequenced. This allowed us to show that the 
elafin gene spans approximately 2.5kb and is split into 3 exons and 2 introns (Fig. 2, Genbank accession number 
AY344541). 
 
Tissue distribution of ovine elafin 
 
Total RNA was extracted from multiple ovine tissues and analysed by Northern blot. A 750bp ovine elafin RNA 
species was detected in tongue, trachea, small intestine, large intestine (strongest signal) and skin (see fig. 3A). 
RT-PCR reaction using primers GSP2 and r-el for ovine elafin was performed using the same RNA samples (see fig. 
3B). Consistent with the Northern blot analysis, we found RNA to be present in tongue, trachea, small intestine, 
large intestine and skin. Interestingly, products of two different lengths were obtained, approximately 660bp (the 
expected size as predicted from the gene sequence) and 800 bp.  
 
Genomic PCR for ovine elafin using a combination of non intron-spanning and intron-spanning primers  
 
On account of isolating two different ovine elafin mRNA products by RT-PCR (see fig. 3B), although only one gene 
was isolated from the BAC library screening, we performed additional PCR reactions using non-intron spanning 
primers and a variety of templates to determine whether these RNA products are splice variants from a single gene 
or products of different/allelic genes. Fig.4A. shows the PCR products when fBAC and rBAC primers are used with 
various templates : genomic ovine DNA (obtained locally), cDNA synthesised by RT-PCR from ovine skin RNA 
(shown to be positive for elafin expression – see fig. 3), DNA extracted from the elafin positive BAC clone, and 
finally DNA extracted from the expression plasmid pIRES-GFP#3 containing the cDNA for ovine elafin isolated by 
RACE-PCR (see above). Two bands were seen with the first two templates (approximately 400bps and 525bps). The 
low molecular weight band corresponded to the ovine elafin cDNA product isolated by RACE-PCR (coding for a 
220 amino acid protein) and present in the pIRES-GFP#3 plasmid containing the ovine elafin cDNA. The higher 
molecular weight band was of unknown origin. The two products obtained with the genomic DNA template were 
isolated and cloned into pCRR4-TOPOR and sequenced. As predicted, the low molecular weight product sequence 
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matched exactly the sequence from the ovine elafin original sequence while the high molecular weight product 
sequence showed an increase in number in PVKGQD repeats (26 instead of 19). The existence of two different 
genomic forms was further confirmed using a different set of PCR primers (the intron-spanning primers GSP2 and r-
el), yielding 2 distinct products of approximately 1500 and 1600bps (not shown). These products were cloned into 
pCRR4-TOPOR and sequenced and confirmed the presence of a second, heavier form of the ovine elafin otherwise 
identical to the original gene isolated by BAC library screening. The original form of the gene described will here 
after be referred to as Trappin Ovine Molecule-1 (TOM-1) and the higher molecular weight form, coding for the 
longer form of ovine elafin of 262 amino acids, will be referred to as TOM-2. Alignment of TOM-1 and the known 
region of TOM-2 are shown in a diagrammatic representation in fig. 4B. 
Southern Blot analysis of ovine genomic DNA (from the same animal as the RNA used in the RT-PCR fig. 3B) is 
shown in fig. 5 and indicates the presence of only one ovine elafin gene showing that indeed TOM-1 and TOM-2 are 
two allelic forms of the same gene.  
  
In vivo up-regulation of ovine SLPI and elafin in response to bacterial lipopolysaccharide 
 
Bronchoalveolar lavage samples were collected one week prior to and 6, 24 and 168 hours after LPS administration. 
Dot blots were performed using these lavages and probed with either a polyclonal antibody against human SLPI or 
the monoclonal antibody Trab-2O to detect ovine elafin (fig. 6).Although both SLPI and elafin concentrations in the 
BALF from LPS treated sheep increase with time compared to pre-experiment values, the kinetics and degree of 
elafin and SLPI up-regulation are different. SLPI increases significantly (1.5 fold) at 6 hours (P<0.0005) and at 24 
hours (P<0.005) while the increase in elafin levels is much more dramatic (8 fold) (P<0.005 at 24 hours). 
 
Protection of A549 cells against proteolytic damage 
 
In order to show potential anti-elastase activity attributable to the protein encoded for by the ovine elafin cDNA, 
A549 cells were infected with Ad-ovine elafin. In order to compare its activity with other known anti-proteases cells 
were also infected with Ad-human elafin and Ad-murine SLPI (fig. 7). Ad-murine eotaxin was used as a negative 
control. Ad-ovine elafin and Ad-human elafin conferred protection of the A549 cells, irrespective of the enzyme 
used. Ad-murine SLPI protected the cells against HNE only, whereas, as anticipated, the negative control Ad-murine 
eotaxin was ineffective against either enzyme. 
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This array of results was obtained using qualitative (fig. 7 panel A) and quantitative (fig. 7 panel B) methods. In 
agreement with the above, the protection by Ad constructs against HNE and PPE activity was paralleled by 
measuring residual enzymatic activity in the supernatants (fig. 7 panel C). 
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Discussion 
 
Neutrophil elastase inhibitors have been shown to be important endogenous molecules involved in limiting the 
extent of neutrophil-induced inflammation in humans, as well as in a variety of animal models (4, 10, 17, 30). 
Among these inhibitors, our group is particularly interested in the study of elafin, a member of the trappin multigene 
family (27). The ‘trappin’ name has been coined by Schalkwijk and collaborators (27) as an acronym for 
TRansglutaminase substrate and wAP (whey acidic protein) domain containing ProteIN, to illustrate its property of 
being ‘trapped’ in a tissue (at least in the skin - 13, 29) and therefore potentially acting as an anchored protein. 
Trappins consist of an N-terminal transglutaminase substrate domain with hexapeptide repeats (PVKGQD), and a C-
terminal four disulphide core, containing, in some members, the antielastase activity (27). Members of this family 
share the WAP domain with another elastase inhibitor, the secretory leukocyte proteinase inhibitor (SLPI). Trappin 
members have been isolated from a number of animal species, including man, but, until now, no studies had 
identified the ovine ortholog of elafin. 
We have in the present study isolated both the genes and cDNA coding for this protein and have analysed the anti-
elastase activity of the translated product. 
 
We have isolated from a trachea sample a cDNA encoding for ovine elafin (o-elafin) which is composed of 220 
amino acids, inclusive of a 23 amino acid signal peptide indicating that the protein is, like other species orthologs, a 
secreted protein (fig. 1 and 2). Following this signal peptide, we identified a region containing nineteen hexapeptide 
repeats of the consensus sequence PVKGQD. A very similar region of repeats has been termed ‘cementoin’ (14) in 
the trappin family of proteins (27) which the elafin members belong to (see above). This glutamine and lysine rich 
region is thought to be involved in a transglutaminase reaction resulting in ε-(γ-glutamyl)lysine covalent bonds 
between the repeat region and matrix proteins such as loricrin and keratin-1, to promote the anchorage of the 
molecule to the interstitium, at least in the skin (13,29). The second domain of o-elafin is composed of a WAP 
domain (27), which has strong homology with o-SLPI which we sequenced (Accession number AY346135) and 
based on the sequence contains the anti-elastase site (see below).  
Using both the ovine genomic BAC library described above and genomic DNA obtained locally, we isolated the o-
elafin gene TOM-1 (Fig. 1, Accession number AY344541), the sequence of which predicted exactly the cDNA 
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sequence obtained from tracheal RNA. The gene structure is similar to that for human elafin (23) in that the gene 
contains 3 exons and 2 introns with similar intron/exon boundaries. 
The promoter region shown contains a ‘TATA’ box at bp 463 but no sequence identifiable as a ‘CAAT’ box. An 
ATG initiation codon was detected, directly 3’ of a consensus Kozak’s sequence (9). The o-elafin leader sequence 
coding for the signal peptide was found to be very similar to other species’ orthologs. 
 
RT-PCR and Northern blot analysis using RNA from various ovine tissues showed o-elafin to be present in tongue, 
trachea, small intestine, large intestine and skin. This is similar to porcine elafin’s distribution where elafin has been 
shown by in-situ hybridisation to be secreted by goblet cells in the tracheal mucosa and large intestinal crypts (31) 
and to human elafin which has been detected in bronchial mucus (19) and psoriatic skin (26, 35) at the protein level, 
and in the epiglottis, pharynx, vocal fold and psoriatic skin at the mRNA level (16). 
To summarise tissue distribution of mRNA, o-elafin is transcribed in the upper respiratory tract, oral cavity, skin and 
gastrointestinal tract. The mainly mucosal tissue distribution of o-elafin is consistent with it being, like its human 
orthologs, an antimicrobial ‘defensin-like’ molecule (20). Indeed, evidence is forthcoming that, in addition to their 
antiprotease activity, SLPI and elafin have important functions in innate immune responses (20). 
Interestingly, we obtained either one or two o-elafin cDNA products, depending on the tissues (fig. 3). The origin of 
the two bands has been shown to be two allelic forms of the same gene (TOM-1 and TOM-2) (fig. 4). The 
differential expression of TOM-1 and TOM-2 in the different tissues is un-explained at present. The reason why we 
only obtained TOM-1 from the BAC library analysis while both TOM-1 and TOM-2 were obtained from genomic 
DNA probably lies with the origin of the samples: indeed, the BAC library used (INRA, France) was derived from a 
different ovine breed (Romanov (34)) from the one used for the RNA and subsequent RACE analysis (Suffolk 
crosses from the UK). Our results suggest that the Romanov breed animal used to construct the BAC library only 
has TOM-1 while the Suffolk breed has both TOM-1 and TOM-2. It is therefore possible that the two allelic forms 
of o-elafin may be caused by the interbreeding of the commercial Suffolk lowland flock. 
The large transglutaminase substrate domain present within the o-elafin molecule is of interest with regards to its 
potential interaction with other tissue components. As mentioned above this region is thought to be involved in 
cross-linking to extracellular matrix proteins at least in the skin. Human elafin has been shown to be cross-linked in 
this way to the cornified envelope of keratinocytes (13, 29). Human elafin contains 5 repeats loosely based on the 
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consensus sequence PVKGQD. The o-elafin orthologs discussed here (TOM-1 and TOM-2) contain 19 or 26 repeats 
with far higher conservation of the consensus sequence, suggesting, potentially, higher levels of transglutaminase-
mediated cross-linking. Interestingly, recent work has implicated transglutaminase repeats to be of importance in 
competitively inhibiting tissue transglutaminase and in turn phospholipase-A2 hence leading to a down-regulation of 
pro-inflammatory mediators in a hypersensitivity model (28). This link between members of the trappin family and 
down-regulation of phospholipase-A2 leads to the fascinating possibility that the extensive transglutaminase 
substrate region of the o-elafin proteins may provide a particularly high anti-inflammatory activity to the secreted 
protein compared to those already studied. The transglutaminase substrate domain has also been identified as one of 
the cis acting elements implicated in the gene multiplication seen in the members of the trappin family (Furutani et 
al identify a correlation between number of repeats and number of trappin family members (3) i.e. the fewest repeats 
are seen in human and peccary in each of which only one trappin family member has been described. Surprisingly, 
given the high number of repeats identified here, we only isolated one trappin, ovine elafin, which was shown to 
exist in two allelic forms. This is the first time a trappin family member gene has been shown to be present in more 
than one allelic form.  
The phylogenetic tree analysis (fig. 8) shows the close relationship between the WAP domain of TOM-1 and TOM-
2, and the other trappin family members, with the second WAP domain of the SLPI orthologs. This suggests a 
divergence in evolution of the trappin WAP motifs and the second SLPI WAP motif from a common ancestral 
protein subsequent to the divergence of the first and second WAP motifs of the SLPI family from each other. 
Interestingly, the hominid trappins (human elafin and simian elafin) have diverged from the rest of the known 
trappins (bovidae, hippopotamidae, tayassuidae and suidae). The two o-elafin proteins (TOM-1 and TOM-2) are 
most closely linked with bovine elafin and bovine trappins 4 and 5.  
In order to ascertain whether the ovine elafin protein is behaving like a local acute phase reactant we assessed the 
levels of ovine elafin in a model of lung inflammation triggered by local bronchoscopic administration of LPS. The 
dramatically increased level of elafin in inflammatory conditions such as described here finds an echo in some of 
our previous in vitro and in vivo human work. We showed (33) that elafin levels were sharply increased in BALF 
from human patients with farmer’s lung disease. By contrast, in the same patients, and in the present study, SLPI 
levels increased less dramatically. This may be due to the increased sensitivity of elafin to pro-inflammatory 
cytokines such as IL-1 and TNF (22). The time courses of elafin and SLPI expression presented here add further to 
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that concept, in agreement with murine SLPI in vivo studies (1, 7). Western blot analysis of broncho-alveolar lavage 
fluid (BALF) for ovine elafin and SLPI using the antibodies utilised in the dot blot analysis above was unsuccessful 
at detecting protein due presumably to the low concentration of these anti-proteases in the BALF.  
 
In summary, the identification and cloning of the gene encoding for the ovine orthologs of human elafin have 
allowed us to postulate important and exciting functions of this protein in addition to the anti-protease functions. 
Furthermore, the in vivo demonstration that ovine elafin is an acute inflammatory reactant in the lung indicates that 
it can be considered as an ‘alarm inhibitor’ in that organ. Its efficiency as a neutrophil elastase inhibitor makes it an 
attractive candidate for use in adenovirus-mediated gene transfer in ovine models of neutrophils-driven lung injury, 
currently being explored in our laboratories. Additionally, specific and potentially very important effects of the 
transglutaminase substrate domain in this protein warrant further investigation. 
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Figure Legends 
 
Fig. 1. Sequence for the gene coding for ovine elafin.  
 
The ‘tata’ box, 5’ Kozak sequence and 3’ polyadenylation signal sequence are boxed. Exons are underlined. 
Predicted signal cleavage site is between amino acids 23 and 23 (between A and A). Annealing sites for the primers 
GSP1, GSP2, r-el (used in RACE-PCR), fBAC, rBAC (used in PCR screening of BAC library) and r-inv-el (used to 
amplify the promoter region) are indicated. 
 
Fig. 2. Comparison of the known elafin protein sequence between species.  
 
The shaded area corresponds to the region of hexapeptide repeats with the consensus sequence PVKGQD. The eight 
conserved cysteine residues within the whey acidic protein domain (WAP) are indicated by asterisks. Where there is 
sequence overlap (ie. ignoring the size difference between the proteins) the ovine elafin sequence shows 70% 
homology at the amino acid level with the simian, 68% with the human, 49% with the porcine and 80% with the 
bovine elafin sequence. 
 
Fig.3. Tissue distribution of ovine elafin RNA as assessed by Northern Blot and RT-PCR. 
 
A. Northern Blot. 20µg of total RNA was loaded for each tissue. Ribosomal 18S and 28S RNA sub-units are 
indicated by arrows. The membrane was probed with the full length cDNA (660bps) corresponding to the 
coding portion of the gene for ovine elafin.  
B. RT-PCR for ß-actin and ovine elafin from RNA extracted from the various organs indicated. The position 
of molecular weight markers is indicated (1kB ladder). Primers used for amplification of ovine elafin were 
GSP2 and r-el yielding two products of approximately 660bps and 800bps.  
 
Fig. 4. The relationship between the two ovine elafin alleles (TOM-1 and TOM-2) coding for proteins of 220 
amino acids and 262 amino acids respectively. 
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A. PCR was performed using the non intron-spanning primers fBAC and rBAC as detailed in the text. 
Templates used were ovine genomic DNA, cDNA synthesised by reverse transcription of RNA isolated 
from ovine skin, DNA isolated from an ovine BAC clone positive by PCR for the elafin gene, and the 
expression plasmid pIRES-GFP#3 containing the cDNA for ovine elafin (220 amino acid form). The lower 
molecular weight product of approximately 400bps is due to amplification of exon 2 of the ovine elafin 
gene or cDNA (and also inserted into pIRES-GFP#3); the longer product of approximately 525 bps 
corresponds to amplification of a longer form of ovine elafin. 
B. The promoter sequence and 3’ sequence is known for the TOM-1 gene only. 100% homology exists 
between the known portion of TOM-2 and the corresponding portion of TOM-1, except for the fact that 
TOM-2 contains 7 extra repeats with the consensus PVKGQD as shown. Numbers below the representation 
of TOM-1 denote base-pairs from the start of the gene sequence.  TOM-2 has been sequenced after PCR of 
ovine genomic DNA using the primers GSP 2 and R-el as shown.  
 
Fig. 5. Southern blot of ovine genomic DNA probed for ovine elafin.  
 
20µg of genomic ovine DNA was digested with restriction enzymes (Xbal, SacI, EcoR1 and BamH1), fractionated 
on a 0.8% agarose gel, then blotted onto a nylon membrane. The membrane was probed with radiolabelled full 
length cDNA corresponding to the coding sequence of TOM-1. The sizes of the bands seen are indicated.  
 
Fig. 6. Secretion of SLPI and elafin in bronchoalveolar lavage collected from sheep lung segments exposed to 
lipopolysaccharide.  
 
1mg E. Coli LPS was administered to discrete lung segments of twelve sheep. Bronchoalveolar lavage was collected 
a week prior to and 6, 24 and 168 hours after administration of the LPS. 200µl of bronchoalveolar lavage from each 
animal at each time point was used in a dot blot and probed with either (A) human anti-SLPI polyclonal antibody, or 
(B) Trab 2-O monoclonal antibody detecting ovine elafin. Results are shown as median arbitrary densitometry units 
against time after dosage of LPS with error bars showing inter-quartile ranges. Also shown are representative dot 
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blot results for each protein. ** signifies a P value of <0.005 and *** signifies a P value of <0.0005 compared to pre 
experimental values when Mann Whitney analysis was performed. All results are based on n=12. 
 
Fig. 7. Ad-ovine elafin protection of A549 cells against human neutrophil elastase and porcine pancreatic 
elastase – correlation with inhibition of enzymatic activity. 
 
Ad-ovine elafin was shown to protect A549 cells against HNE and PPE (1µg/ml) (panel A). By contrast, the 
negative control Ad-murine eotaxin provided no protection against either enzyme. Ad-human elafin protected cells 
against both HNE and PPE whereas Ad-murine SLPI was efficient only against HNE (panel A).These data were 
confirmed quantitatively, when protein concentration was assessed as a surrogate marker of cell damage (panel B 
and Materials and Methods). The protection (or lack of) conferred (panels A and B) by the Ad constructs against 
proteolytic enzymes was paralleled by the residual enzymatic activity recovered in cell culture supernatant (panel 
C). ** : signifies P<0.005, *** : P<0.0005 compared to Ad-murine eotaxin with Mann-Whitney analysis, n=5 
(HNE) or 6 (PPE).  
 
Fig. 8. Whey acid protein (WAP) comparison (SLPI, trappins, mouse elafin-like proteins, vasopressin).  
 
A. Alignment of the 1st and 2nd WAP domains of the currently known SLPI proteins, along with the WAP 
domains for a variety of trappins including the ovine forms of elafin derived from the alleles TOM-1 and 
TOM-2, and including the WAP domains of the murine elafin-like proteins 1 and 2 (Hagiwara et al) and 
human vasopressin. The WAP motifs for all the proteins were aligned by using ClustalW software 
available online. Conserved cysteine residues are indicated by asterisks. The boxed region indicates the 
putative active anti-protease active site in the second WAP domains of the SLPI family and in the WAP 
domain of the trappin family.  
B. Phylogenetic tree constructed using a neighbour-joining technique with Poisson corrected data from the 
above alignment. Bootstrap values above 40 are indicated. Branch length is proportional to evolutionary 
distance.  
ACTTTCTTGGTGCATTTCAGAGGCTGCCTGTGAAATGGAAAAGTATAATG 50
--------------------------------------------------
ATTAGTCATTAAACACTCAGGGCAAATTTGCCTTTGAGAGTTTTTCTTGG 100
--------------------------------------------------
GATCAGGGGGAGAATGAAAGAAAAGCCTAGCATGATGCTGGGAAGAATAA 150
--------------------------------------------------
ATTGTTAGGGTAGGTCTGGGTGGGGCTTGCAGGAGCTGGGGAGAAATGGG 200
--------------------------------------------------
GGAACACCTTGGCTATACAAACAGTACTCCAGACCTACCACTGACTTGTT 250
--------------------------------------------------
GAATGACTGTGGGCGATTCCTCTCTCTCCTTTGGGCTTCATATTCTTTAA 300
--------------------------------------------------
GTATAAAGAATTTGGTCATGACGGTGCCTACAGACCAGCCAGCCCTACTT 350
--------------------------------------------------
CTTTGTGAGAATGTGAGATAGCTCTTGGGGCTATTAGAAATGATGTAACA 400
--------------------------------------------------
GCCATTTCTCCCTGTGGATAATCCTTGGGGAAGGGCCCAAGGTCCCTCCC 450
--------------------------------------------------
AGGATGAGGGTGTATATTTCCTGGTAAAACTAAGAAAATTTAAGTCTTAT 500
--------------------------------------------------
CCCTTGTGAAACCACAGACCCACCCTTGGCACCTGGCCAAGCTGAAGCTG 550
--------------------------------------------------
 GSP2→
CATAAAACTAGGCTTCAGCTCTCAGTCATACATCTTCTTGACAACATGAA 600  
---------------------------------------------  M K
GACCAGAAGCTTCTTGGTCCAGGTGGTGGTGCTTCTCATCCTTGGGACGC 650  
 T R S F L V Q V V V L L I L G T
TGGTGGCAGAGGCAGCTATCATAAGAGGTGAGTGGACAAGTGGCCTGGGT 700  
L V A E A A I I R |----------------------
GAGGCTGGCTTGGGTTGAGGAGAGGTTGTTAGGGGCAGCCTGGGTCTTGA 750
-----------------------INTRON1--------------------
      ←r-inv-el
CAAGGGGCAGCATGCAGAGCTGGAGCCCACTCTTTAGCCTGGACAGCAGG 800
-----------------------INTRON1--------------------
CTAAAGTTTTGAGTGTATCCAGAGATGTAGGAAGTTGCCCACTAGATTCC 850
-----------------------INTRON1--------------------
ATGTACATTCTCCCCAGGACTGAAAATCAGGGCTGTTTGTGGAAGGAGTG 900
-----------------------INTRON1--------------------
TTGTAACATGACCTTGGCCTCAAGCACTGATACTTGGACAGAACATGCAA 950
-----------------------INTRON1--------------------
TGAAGTTGAGGAGCCCAGGAATCTGGGCCCTGGGTGGTGTCTCTTCCCTG 1000
-----------------------INTRON1--------------------
CCTGTTTGCTCCATCAAAGCACCTGAGTCATCAGTCCTGTAAGGGGAGGT 1050
-----------------------INTRON1--------------------
TAAGAACTAACAGGGCCTCAGAAATCATGGAGTCTGAAGACCTCTGTTTT 1100
-----------------------INTRON1--------------------
CCAAAGCAGGACACCGAGACCTAGAGCAAGGTGAGGAATTGTCAGGGCAA 1150
-----------------------INTRON1--------------------
TCTCCAGAGCCAGGCTGGAGCTCAGGTCTCCTGGCATTTGTCTCAAAGCT 1200
-----------------------INTRON1--------------------
CCTTGCCCTTCCACCAAGTTTCCTCAAAGATGACAATGTGTCCTCATCTC 1250
-----------------------INTRON1--------------------
CTGAAAGTCACTCCTCCCTGGCATATCCTCATGAGGGCCCCAAGACCCAG 1300
-----------------------INTRON1--------------------
AATGGAGGGTGAGGGGAAGAAATGGACACCCAAAGGAAACCTGGTCCTAT 1350
-----------------------INTRON1--------------------
GGACCTTTTCTCCAAAGCCCAGGGAACAGCCATCCAAGAGTGCAGACCCT 1400
-----------------------INTRON1--------------------
AGCTAGCCCTGGTGAGCCTCCTCTGTCTCAGTGTCCCTCAGCTTAAGGGA 1450
-----------------------INTRON1--------------------
CACCGCAGTAAGCAGTGGCTGGACCTGGAGGAAAGACTAGATAGTTGAAG 1500
-----------------------INTRON1--------------------
CAGACATGCTGGTCTAAATATTAGTAATAGTAGGGATATTTCTTTCAACA 1550
-----------------------INTRON1--------------------
GGTCGTCCAAAAGGTCAAGGTACTAAGAAAACAAATGTTTTAGTCAATGA 1600  
|G R P K G Q G T K K T N V L V N E
fBAC→
AAAGGGTCCAATCAACGGTCAATATCCTGTCAAAAGACCAAATCCAGTGA 1650  
 K G P I N G Q Y P V K R P N P V
AAGGTCAAGGTCCAGTGAAAGGTCAAGATCCAGTGAAAGGTCAAGATCCA 1700 
K G Q G P V K G Q D P V K G Q D P
GTCAAAGGTCAAGATCCAGTCAAAGGACAAGATCCAGTCAAAGGTCAAGA 1750  
 V K G Q D P V K G Q D P V K G Q D
TCCAGTCAAAGGACAAGATCCAGTCAAAGGTCAAGATCCAGTCAAAGGAC 1800  
 P V K G Q D P V K G Q D P V K G
AAGATCCAGTCAAAGGTCAAGATCCAGTCAAAGGACAAGATCCAGTCAAA 1850  
Q D P V K G Q D P V K G Q G P V K
GGTCAAGATCCAGTCAAAGGTCAAGATCCAGTCAAAGGTCAAGGTCCAGT 1900  
 G Q D P V K G Q D P V K G Q G P V
CAAAGGACAAGATCCAGTCAAAGGTCAAGATCCAGTCAAAGGTCAAGATC 1950  
 K G Q D P V K G Q D P V K G Q D
CAGTCAAAGGACAAGACCGAGTCAGAAGTCCACTCCTCACTAAGCGTGGC 2000  
P V K G Q D R V R S P L L T K R G
←rBAC ←GSP1
TCCTGCCCCAGGGTTCTGATCCGGTGCGCCATGATGAACCCCCCTAACCG 2050  
       S C P R V L I R C A M M N P P N R
GTGTCTGAGAGATGCTCAGTGCCCAGGGGCCAAGAAGTGCTGTGAAGGCT 2100  
 C L R D A Q C P G A K K C C E S
    ←r-el
CTTGTGGGAAGACCTGTATGGATCCCCAGTGAGGTGAGAAATGGGTGGAG 2150  
S C G K T C M D P Q END |----------------
GGAAAGGTGGCCCATGAGGGTGCAGAGAGGCCAACTGGCAGAGTGCAATC 2200
-----------------------------INTRON2--------------------
CTAGGCTATGGGGGAAAGGACACGGGAGGTGATGGAGAGACTGAGGGGTC 2250
-----------------------INTRON2--------------------
TCAGGGGCTACAGCTGGGGTCCTGAGAAGGATGGCATGTGGACTTGGCCC 2300
-----------------------INTRON2--------------------
TGCCTCCCACTGCCTCTGAGTCTTCCACCTGCTGACTCTCATTTTCGATT 2350
-----------------------INTRON2--------------------
CTTTCTCTTTTCTTCCACCAGGTAGAGTCTGTGCTTGCTGCACCTGTGAG 2400  
--------------------|--3’UTR----------------------
GTCCCCAGGGATGTAGGCCCTGGTGCCTGTAGCATGACCCTCTCCCACAC 2450  
-----------------------3’UTR----------------------
TGCCCCTTCTTCCTCTCAGCCAGGAGGCCCAAGCTTGAGCATGGACTGCT 2500  
-----------------------3’UTR----------------------
TCCCTCGTGAACTTTCCA  ATAAAA     2524  
Fig. 1 
      1            15 16           30 31           45 46           60   
     simian  ---------VVVFLI AGMLVVEAA------ --------------- ---------------  
     human   MRASSFLI-VVVFLI AGTLVLEAA------ --------------- ---------------  
     porcine MRSRSFLVLVVVFLI CGTLVAQAAGRIRRP KGKGTKKILALV--- ---------------  
     bovine  --------------- --------------- --------------- ---------------  
     ovine   MKTRSFLVQVVVLLI LGTLVAEAAIIRGRP KGQGTKKTNVLVNEK GPINGQYPVKRPNPV  
 
      61           75 76           90 91          105 106         120  
     simian  -----------VTGV -PVKGQDTVKGRVPF NGQDPVKGQVSVKGQ DRVKGRGPVKG----  
     human   -----------VTGV -PVKGQDTVKGRVPF NGQDPVKGQVSVKGQ DKVKAQEPVKG----  
     porcine KGQGPVRGKDQVKGQ GPVKGQDLGKSQDPV KAQLPDKGQDLGKGE DSVKGQDPFKAQ---  
     bovine  --QEPVKGQDPVKGQ DPVKGQDPVKGQDPV KDQNPVRGQEPVKGQ DPVKGQDPVKGQDPV  
     ovine   IGQGPVKGQDPVKGQ DPVKGQDPVKGQDPV KGQDPVKGQDPVKGQ DPVKGQDPVKGQDPV  
 
      121         135 136         150 151         165 166         180  
     simian  --------------- --------------- --------------- -----PVSTKPGSCP      
     human   --------------- --------------- --------------- -----PVSTKPGSCP      
     porcine --------------- ------------LPD KLQDPVKAQPAIK-- ---RLILLTKPGSCP     
     bovine  KGQ------------ ------------EPV KGQDPVKGQDPVKRQ GRIGGPLLTKPGSCP     
     ovine   KGQGPVKGQDPVKGQ DPVKGQGPVKGQDPV KGQDPVKGQDPVKGQ DRVRSPLLTKRGSCP     
           * 
      181         195 196         210 211            
     simian  NILIRCAMLNPPNRC LKDTD---------- ----------     89 
     human   IILIRCAMLNPPNRC LKDTDCPGIKKCCEG SCGMACFVPQ    117 
     porcine RILIRCLMVNPPNRC LSDAQCPGLKKCCEG FCGKACMDPK    167 
     bovine  RVLIRCAMMNPPNRC LRDAQCPGVKKCCEG SCGKTCMDPQ    134 
     ovine   RVLIRCAMMNPPNRC LRDAQCPGAKKCCES SCGKTCMDPQ    220 
    *    *   * **    *   * 
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Fig. 7 
human SLPI WAP 1              CPPK-KS-AQ C--LRYKKPE -CQSDWQCPG KKR-CCPD-T CG--IKC
ovine SLPI WAP 1              CPPR-KS-AQ C--FGNEKPR -CSSDWQCPH KKK-CCLD-T CG--TEC
rat SLPI WAP 1                CPAR-KP-AQ C--LKREKPE -CSTDWGCPG KQR-CCQD-T CG--FKC
murine SLPI WAP 1             CPAK-KP-AQ C--LKLEKPQ -CRTDWECPG KQR-CCQD-A CG--SKC
porcine SLPI WAP 1            CPPR-KI-VQ C--LRYEKPK -CTSDWQCPD KKK-CCRD-T CA--IKC
human SLPI WAP 2              CPVT-Y--GQ C--LMLNPPN FCEMDGQCKR DLK-CCMG-M CG--KSC
ovine SLPI WAP 2              CPVI-H--GQ C--LMLKPLN HCETXDQCIG ALK-CCKA-M CG--KVC
rat SLPI WAP 2                C-LK-FQ-GK C--LMLNPPN KCQNDGQCDG KYK-CCEG-M CG--KVC
murine SLPI WAP 2             C-VK-TQ-AR C--MMLNPPN VCQRDGQCDG KYK-CCEG-I CG--KVC
porcine SLPI WAP 2            CPVV-Y--GQ C--MMLNPPN HCKTDSQCLG DLK-CCKS-M CG--KVC
TOM-1 WAP                     CP-R-VL-IR C--AMMNPPN RCLRDAQCPG AKK-CCES-S CG--KTC
TOM-2 WAP                     CP-R-VL-IR C--AMMNPPN RCLRDAQCPG AKK-CCES-S CG--KTC
simian elafin WAP             CP-N-IL-IR C--AMLNPPN RCLKDTD--- ---------- -------
human elafin WAP              CP-I-IL-IR C--AMLNPPN RCLKDTDCPG IKK-CCEG-S CG--MAC
porcine elafin WAP            CP-R-IL-IR C--LMVNPPN RCLSDAQCPG LKK-CCEG-F CG--KAC
warthog elafin WAP            CP-R-IL-IR C--MMVNPPN RCLSDAQCPG VKK-CCEG-F CG--KEC
bovine elafin WAP             CP-R-VL-IR C--AMMNPPN RCLRDAQCPG VKK-CCEG-S CG--KTC
porcine trappin 1 WAP         CP-R-IL-FR C--PLSNPSN KCWRDYDCPG VKK-CCEG-F CG--KDC
warthog trappin 3 WAP         CP-W-IL-LR C--PLANPSN KCWRDYDCPG VKK-CCEG-F CG--KDC
bovine trappin 4 WAP          CP-R-VL-FK C--LVMNPPN RCLRDAQ--- ---------- -------
bovine trappin 5 WAP          CP-R-VL-FK C--LVMNPRN RCLRDVQC-- ---------- -------
bovine trappin 6 WAP          CP-R-VR-IH C--NLWNPPN QCWRDAHCPG AKK-CCEG-F CG--KTC
porcine trappin 7 WAP         CP-W-IF-LR C--PLPKPPN KCWRDSHCPG VMK-CCEG-F CG--NEC
porcine trappin 8 WAP         CP-R-IL-IR C--LMVNPPN RCLSDAQCPG VKK-CCEG-F CG--KDC
porcine trappin 9 WAP         CP-R-IE-IR C--RLLNP-N RCLIDAQCPG FQK-CCR--V CGV-KSC
peccary trappin 10 WAP        CP-M-IK-IR C--ALFNPPN RCLTDAGCPG ARK-CCIG-S CG--KAC
hippopotamus trappin 11 WAP   CP-K-IW-IE C--STLNPPK RCLRDAQCPR NKN-CCPA-S CG--KIC
elafin-like protein 1 WAP     CP-E-YR-VP CPFVLI--PK -CRRDKGCKD ALK-CCFF-Y CQM-R-C
elafin-like protein 2 WAP 1   CP-E-FL-LD CPFVLL--PV -CSRDKGCKG TKK-CCFY-Y CQM-RIL
elafin-like protein 2 WAP 2   -P-D-YV-R- C--IRQDDPQ -CYSDNDC-G DQEICCFW-Q CGF-K-C
human vasopressin             CQEENYLPSP C---QSGQKA -CGSGGRCAA FGV-CCNDES CVTEPEC
*        *  *     *       **     *     *
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